Form 4: ANI Pharmaceuticals SVP, Generics, Ori Gutwerg, Reports Stock Transactions
SEC Form 4 Filing
Ori Gutwerg, SVP, Generics at ANI Pharmaceuticals, reported the acquisition and disposal of company stock on March 5, 2025, including the exercise of stock options and sale of shares.
Summary
- On March 5, 2025, Ori Gutwerg, SVP, Generics at ANI Pharmaceuticals, executed transactions involving the company's stock.
- Gutwerg exercised stock options to acquire 300 shares at a price of $31.49 per share.
- Gutwerg disposed of 300 shares at $60.03 and 5,084 shares at a weighted average price of $60.00.
- Following these transactions, Gutwerg directly owns 94,092 shares of ANI Pharmaceuticals.
- Gutwerg also directly owns 13,204 stock options.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of insider trading activity. The transactions themselves don't necessarily indicate a positive or negative outlook for the company.
Industry Context
Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders.
Stakeholder Impact
- Shareholders are informed about the transactions of a key executive, providing transparency into insider activity.
Key Dates
| Date | Description |
|---|---|
| 02/15/2022 | 25% of stock options vested |
| 02/15/2023 | 25% of stock options vested |
| 02/15/2024 | 25% of stock options vested |
| 02/15/2025 | 25% of stock options vested |
| 03/05/2025 | Earliest transaction date: Stock options exercised, shares sold |
| 03/07/2025 | Date of report signature |
| 02/15/2031 | Expiration date of stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.